Skip to content

The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture

The Diagnostic Application of PSMA PET/MR in Patients with PSA <20 Ng/ml and Initial Negative Prostate Biopsy

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06901492
Enrollment
120
Registered
2025-03-30
Start date
2025-06-01
Completion date
2028-06-01
Last updated
2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MpMRI, Prostate Cancer, PSMA PET/CT

Keywords

Prostate cancer, PSMA PET/CT, mpMRI, Prostate biopsy

Brief summary

The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy

Interventions

DIAGNOSTIC_TESTProstate biopsy guided by PSMA PET/CT

The patient will undergo pelvic non-contrast CT imaging. After co-registration of the CT images with 68Ga-PSMA PET/CT data at corresponding anatomical levels, a percutaneous gluteal approach will be utilized for CT-guided prostate biopsy.

DIAGNOSTIC_TESTProstate biopsy guided by mpMRI/US

The patient will undergo transrectal ultrasound (TRUS) prostate scanning. After co-registration and precise image fusion of TRUS findings with multiparametric MRI (mpMRI) data, a transperineal percutaneous approach will be employed to perform TRUS-guided prostate biopsy.

DIAGNOSTIC_TESTSystematic prostate biopsy

The patient will undergo systematic prostate biopsy under TRUS guidance.

Sponsors

Nanjing First Hospital, Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥40 years, male; 2. Serum PSA level 4-20 ng/mL; 3. Serum PSA level 4-20 ng/mL; 4. No contraindications to PSMA-PET/CT or MRI; 5. Signed informed consent.

Exclusion criteria

1. Serum PSA \>20 ng/mL; 2. History of prostate surgery/radiotherapy; 3. Acute prostatitis; 4. Coagulation disorders or active infection; 5. Severe internal/external hemorrhoids, perianal, rectal, or gluteal lesions; 6. Allergy to local anesthetics; 7. Inability to tolerate the biopsy procedure.

Design outcomes

Primary

MeasureTime frameDescription
Biospy outcome12 monthsCompare the diagnostic value (including sensitivity, specificity, NPV and PPV) between puncture methods and set up a diagnostic model.

Secondary

MeasureTime frameDescription
Duration of puncture operation12 monthsRecord the time required for each patient's puncture procedure
Patient's pain level12 monthsBased on VAS pain score
Blood loss12 monthsBleeding volume during and after operation
Complication12 monthsComplications during and after the operation, including urethral injury, hematuria, and urinary tract infection, etc.

Countries

China

Contacts

Primary ContactHongbin Sun Sun, MD, PHD
docshb@126.com+86-02552271061

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026